Cost-Effectiveness of Follitropin Delta versus Follitropin Alfa in Controlled Ovarian Stimulation for IVF/ICSI Cycles in China
Author(s)
Sheng Han, Professor1, Rui Yang, Professor2, Xiaodong Guan, Professor3, Jérémy CARETTE, PharmD4, Marie Markert, MSc5, Chao Liu, MSc6, Jie Qiao, Professor2;
1International Research Centre for Medicinal Administration, Peking University, Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Beijing, China, 2Peking University Third Hospital, National Clinical Research Center for Obstetrics and Gynecology, Dept. of Obstetrics and Gynecology, Beijing, China, 3International Research Centre for Medicinal Administration, Peking University, Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical, Beijing, China, 4Public Health Expertise, Paris, France, 5Ferring Pharmaceuticals A/S, Kastrup, Denmark, 6Ferring Pharmaceuticals (Asia), Shanghai, China
1International Research Centre for Medicinal Administration, Peking University, Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Beijing, China, 2Peking University Third Hospital, National Clinical Research Center for Obstetrics and Gynecology, Dept. of Obstetrics and Gynecology, Beijing, China, 3International Research Centre for Medicinal Administration, Peking University, Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical, Beijing, China, 4Public Health Expertise, Paris, France, 5Ferring Pharmaceuticals A/S, Kastrup, Denmark, 6Ferring Pharmaceuticals (Asia), Shanghai, China
Presentation Documents
OBJECTIVES: Follitropin delta (Rekovelle) is a recombinant follicle-stimulating hormone (rFSH) used in controlled ovarian stimulation (COS) for IVF/ICSI cycles. It is delivered in a pen and offers personalized dosing based on patient's ovarian reserve profile (anti-Müllerian hormone (AMH) levels) and body weight. It provides individualized fixed daily dosing avoiding the need for dose adjustments, while maintaining a favourable safety/efficacy profile. The objective of this analysis is to assess the cost-effectiveness of Rekovelle compared with Gonal-F for women undergoing COS for IVF/ICSI cycles in China.
METHODS: A decision-tree model was developed comparing the outcomes of treatment with Rekovelle versus Gonal-F through ongoing pregnancy (OP) and live birth (LB) in fresh cycles, using data from the pan-Asian GRAPE trial. The analyses were stratified by age and ovarian reserve profile and reflected a single COS cycle. Costs were estimated from the Chinese treatment setting perspective, and uncertainty was assessed through sensitivity analyses.
RESULTS: Rekovelle achieved non-inferiority of OP (31.3% vs 25.7% [diff 5.4% CI: -0.2%;11.0%]) in its individualized dosing regimen compared with Gonal-F in conventional dosing, but significantly higher rate of LB (31.3% vs 24.7% [diff 6.6% CI: 0.9%; 11.9%]; P=0.023) in the GRAPE trial. The mean total dose was 78 µg for Rekovelle versus 110 µg for Gonal-F. In the economic model, the total treatment cycle costs were estimated at ¥25,689 for Rekovelle and ¥27,189 for Gonal-F. Excluding cost of delivery, the total costs were ¥23,255 and ¥25,214, respectively. Hence, Rekovelle was a dominant treatment option. Sensitivity analyses supported the deterministic results, showing >89% probability of Rekovelle being dominant with OP endpoint and >82% probability of being dominant with the LB endpoint.
CONCLUSIONS: Rekovelle is cost-effective compared with Gonal-f in COS for IVF/ICSI cycles in China. This is attributed to improved OP and LB rates with a lower total dose of FSH.
METHODS: A decision-tree model was developed comparing the outcomes of treatment with Rekovelle versus Gonal-F through ongoing pregnancy (OP) and live birth (LB) in fresh cycles, using data from the pan-Asian GRAPE trial. The analyses were stratified by age and ovarian reserve profile and reflected a single COS cycle. Costs were estimated from the Chinese treatment setting perspective, and uncertainty was assessed through sensitivity analyses.
RESULTS: Rekovelle achieved non-inferiority of OP (31.3% vs 25.7% [diff 5.4% CI: -0.2%;11.0%]) in its individualized dosing regimen compared with Gonal-F in conventional dosing, but significantly higher rate of LB (31.3% vs 24.7% [diff 6.6% CI: 0.9%; 11.9%]; P=0.023) in the GRAPE trial. The mean total dose was 78 µg for Rekovelle versus 110 µg for Gonal-F. In the economic model, the total treatment cycle costs were estimated at ¥25,689 for Rekovelle and ¥27,189 for Gonal-F. Excluding cost of delivery, the total costs were ¥23,255 and ¥25,214, respectively. Hence, Rekovelle was a dominant treatment option. Sensitivity analyses supported the deterministic results, showing >89% probability of Rekovelle being dominant with OP endpoint and >82% probability of being dominant with the LB endpoint.
CONCLUSIONS: Rekovelle is cost-effective compared with Gonal-f in COS for IVF/ICSI cycles in China. This is attributed to improved OP and LB rates with a lower total dose of FSH.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE195
Topic
Economic Evaluation
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Reproductive & Sexual Health